Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Systemic Therapy +/- LCT in Limited Metastatic NSCLC
NCT03137771Phase 2Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Apr 2017
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NRG Oncology. Primary endpoints: Progression-free Survival up to 5.4 years and Overall Survival up to 5.4 years. Started Apr 2017; status: active, not recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03137771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03137771.